Welcome to our dedicated page for NOVN news (Ticker: NOVN), a resource for investors and traders seeking the latest updates and insights on NOVN stock.
Novan, Inc. (NOVN) is a clinical-stage biotechnology innovator harnessing nitric oxide's therapeutic potential for dermatological and antiviral treatments. This page provides essential updates on the company's strategic developments, clinical progress, and regulatory milestones.
Investors and industry observers will find comprehensive coverage of Novan's recent $15 million asset sale process, including Bankruptcy Court proceedings and DIP credit facility repayment. The resource also tracks ongoing advancements in the company's core pipeline targeting acne, psoriasis, and oncovirus-mediated conditions.
Key content includes updates on therapeutic candidate development, partnership announcements with pharmaceutical leaders, and financial restructuring developments. All information is curated to meet the needs of both professional analysts and informed public stakeholders.
Bookmark this page for timely updates on Novan's unique nitric oxide platform and its applications in addressing unmet medical needs through innovative biotechnological solutions.
Novan, Inc. (Nasdaq: NOVN) will host its 2020 Annual Meeting of Stockholders (ASM) on July 28, 2020, at 9:30 a.m. ET via a live audio webcast due to the COVID-19 pandemic. Stockholders of record as of June 11, 2020, can vote electronically and ask questions during the meeting. Guests may listen but cannot submit questions. Online check-in starts at 9:15 a.m. ET. Novan is focused on using nitric oxide for treating various diseases, emphasizing its potential benefits in dermatology and women's health.
Novan anticipates its cash position will cover costs for an additional Phase 3 pivotal trial for SB206, targeting molluscum treatment (B-SIMPLE4). The company has secured approximately $16.9 million since June 1, 2020, from stock purchase agreements and warrant exercises. Enrollment for the trial is set for September 2020, with top-line results expected in late Q2 2021, pending no COVID-19 disruptions. Notably, there are currently no FDA-approved therapies for molluscum, highlighting the unmet need SB206 aims to address.
Novan, Inc. (Nasdaq: NOVN) will present a corporate overview at the Life Sciences Investor Forum on June 25, 2020, at 2:00 p.m. Eastern. CEO Paula Brown Stafford will lead the presentation, which will include a real-time Q&A session for investors. Attendees can access the live webcast via the Company's website. An archived version will be available post-event. Novan, a clinical development-stage biotechnology company, focuses on leveraging nitric oxide to treat various diseases, addressing significant unmet medical needs.
FAQ
What is the market cap of NOVN (NOVN)?
